X4 Pharmaceuticals Inc XFOR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XFOR is a good fit for your portfolio.
News
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
-
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
-
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
-
Thinking about buying stock in Marpai, Axcelis Technologies, Amylyx Pharmaceuticals, Biomx, or X4 Pharmaceuticals?
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $1.36
- Day Range
- $1.21–1.39
- 52-Week Range
- $0.57–2.58
- Bid/Ask
- $1.26 / $1.27
- Market Cap
- $206.56 Mil
- Volume/Avg
- 3.5 Mil / 2.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 93
- Website
- https://www.x4pharma.com
Comparables
Valuation
|
Metric
|
XFOR
|
KROS
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.46 | 5.35 | 12.65 |
Price/Sales | — | — | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
XFOR
KROS
CBAY
Financial Strength
|
Metric
|
XFOR
|
KROS
|
CBAY
|
|---|---|---|---|
Quick Ratio | 5.02 | 13.63 | 10.70 |
Current Ratio | 5.34 | 14.25 | 10.96 |
Interest Coverage | −17.29 | — | −5.27 |
Quick Ratio
XFOR
KROS
CBAY
Profitability
|
Metric
|
XFOR
|
KROS
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −64.54% | −35.62% | −30.06% |
Return on Equity (Normalized) | −160.11% | −39.15% | −51.97% |
Return on Invested Capital (Normalized) | −91.49% | −41.95% | −30.87% |
Return on Assets
XFOR
KROS
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rgsxtnnhyy | Xtlqy | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ksmptkvd | Fbvnshm | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nnwkwrbrr | Qlstdv | $98.8 Bil | |
MRNA
| Moderna Inc | Tbrqqzrxd | Thzx | $38.8 Bil | |
ARGX
| argenx SE ADR | Yqvsjkk | Dsvm | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Mfdmyhxg | Dyy | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sdbwchlf | Wmrzcr | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yyhdygmw | Ztrpck | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gzbgstfz | Mcxftr | $12.4 Bil | |
INCY
| Incyte Corp | Drcndxct | Phppspj | $11.9 Bil |